Wilson’s Disease: Diagnosis in Novel Way

Pankaj K. Kannauje 1, Vinay R. Pandit 1, Preetam N. Wasnik 1, Pranita Das 1, Nanditha Venkatesan 1

1. General Medicine, All India Institute of Medical Sciences, Raipur, IND

Corresponding author: Pankaj K. Kannauje, drpankajkannauje@aiimsraipur.edu.in

Abstract

Wilson’s disease first described by Kinnier Wilson in 1912, is a rare autosomal recessive genetic disorder involving a defect in copper metabolism. This disease affects between one in 30,000 to one in 100,000 individuals and has a carrier frequency of one in every 90. It is characterized by hepatic and neurological symptoms. The usual age of presentation is 4 to 40 years but this disorder has been detected in children as young as three years and adults as old as 70 years with males and females being equally affected. Diagnosing Wilson’s disease at the earliest is crucial as it is not only progressive and fatal if untreated, but also responds promptly to medication. Here we are going to present a novel way to diagnose a case of Wilson disease in a resource-limited setting. The diagnosis was possible with detailed present and past history raising strong clinical suspicion of environmental or genetically related disease. The diagnosis was done in a novel way by first diagnosing in daughter thereafter confirming the same diagnosis in patient.

In the era of Wilson disease, the disease presents with various symptoms and signs. The diagnostic criteria for Wilson disease are quite complex and involve a combination of various investigations such as serum ceruloplasmin, 24-hour urinary copper test, and liver biopsy. However, in our case, due to financial constraints, the patients’ daughters refused the aforementioned tests.

Case Presentation

A 50-year-old female patient was brought to the emergency department of our hospital by her two young daughters. Patient was crying furiously, shouting gibberish atop her voice. The daughters revealed that this was a common occurrence and noted that the patient had abnormal posturing, which was corroborated by general examination.

On further enquiry, the daughters reported observing a few cases of rigidity in their hometown with similar behaviors.

With this vital information, diseases with environmental exposure and geographical location were considered, and Wilson’s disease was considered a differential diagnosis. To rule out Wilson’s disease, we have done routine investigations and recommended serum ceruloplasmin, 24 urinary copper test, and liver biopsy for confirmation. However, owing to financial constraints, the daughters reluctantly refused the aforementioned tests. We decided to look for the Kayser-Fleischer (KF) ring in the patient, but she was uncooperative, making it almost impossible to test her. Her Hemoglobin was 10.8 g/L, platelets 178 x109/L, WBC count of 6.06x109/L. Her liver function test showed normal bilirubin level with serum glutamic-oxaloacetic transaminase (SGOT)-24 IU/L, serum glutamic pyruvic transaminase (SGPT)-32 IU/L, alkaline phosphatase - 110 IU/L, total protein 6.2 gm/dL, and albumin 4.1 g/dL. Her prothrombin time (PT) was 12.2 seconds, international normalized ratio (INR 1.1), and activated partial thromboplastin time (aPTT) of 29.5 seconds. Her ultrasound abdomen showed normal liver size (10.8 cm) and normal portal vein diameter (8 mm) without any evidence of cirrhosis (Figure 1).
Considering environmental exposure and genetic predisposition, we planned to look for KF ring in the daughters. Any form of genetic pigmentation was ruled out, and the elder daughter subsequently tested positive for the KF ring (Figure 2).
Using that as leading evidence, we shared the cost of 24h urinary copper test for the patient and her elder daughter, and the level of copper in both individuals was markedly high, confirming our suspicion. The Leipzig score was calculated for the patient and it was >4 confirming the diagnosis of Wilson. The patient was started on D-penicillamine (500 mg), aspirin (75 mg), and zinc (100 mg). The patient drastically improved, and after staying for three weeks she was discharged. The patient and elder daughter are on regular follow-up and doing well.

Discussion

Wilson’s disease is caused by mutations in the ATP7B gene, which regulates the protein transporters that excrete excess copper via bile [1,2]. The lack of adequate excretion and accumulation of excess copper in the blood lead to oxidative stress and damages to the cells, leading to clinical manifestations [3].

As the disease affects the liver and basal ganglia, symptoms usually are primarily related to the liver and brain. Liver-related signs and symptoms include jaundice, itching, abdominal pain, generalized weakness, vomiting, and ascites. Neurological signs and symptoms include tremors, chorea, personality changes, depression, anxiety, headaches, insomnia, seizures, hallucinations, ataxia, and mask-like facies.

On examination, the stigmata of chronic liver disease are often observed, if the disease has progressed. Slit-lamp examination will reveal KF rings on the cornea. Moreover, skeletal involvement, similar to premature osteoarthritis and arthropathy, is common. Hemolytic anemia, Fanconi syndrome-like symptoms and urolithiasis are also observed in some patients.

For clinical suspicion, examining the serum levels of ceruloplasmin is recommended as the first-line diagnostic test. Values of less than 20 mg/dL (normal 20–40 mg/dL) favor Wilson’s disease but can be normal in few cases. However, it is prudent to consider that low ceruloplasmin levels may be observed in nay protein-deficiency order. Urinary copper levels higher than 100 µg/dL indicate excess copper in the circulation. These two diagnostic tests along with KF ring are adequate to diagnose Wilson’s disease. However, the gold standard for diagnosis remains liver biopsy to determine liver copper levels. A positive result is a copper level of greater than 250 µg/g dry liver tissues [4].

Magnetic resonance imaging (MRI) is required for cases with brain involvement. MRI T2-weighted sequence
may show hyperintensities in the basal ganglia and demonstrate the characteristic “face of the giant panda” pattern. Screening of first and second-degree relatives is advised.

Differential diagnoses include conditions causing chronic active hepatitis, primary biliary cirrhosis and hemolytic anemias due to various causes. Neuropsychiatric disorders that can be mistaken include various types of parkinsonian syndromes, pantothenate kinase deficiency associated with neurodegeneration (iron accumulation), neuroacanthocytosis syndromes, and Huntington’s disease among others. These conditions may present with personality changes, rigidity, dystonia, and movement disorders and cause confusion during diagnosis.

Due to difficulties in diagnosing Wilson’s disease, the Leipzig (Ferenci) score was devised by a group of experts to help diagnose patients (Table 1).

| Typical clinical signs & symptoms | Other tests                                                                 |
|----------------------------------|-----------------------------------------------------------------------------|
| KF ring                          | Liver copper (in the absence of cholestasis)                                |
| Present                          | 2 >5x ULN (>4µmol/g)                                                       | 2 |
| Absent                           | 0 0.8-4 µmol/g                                                             | 1 |
| Neurologic symptoms              | Normal <0.8 µmol/g                                                          | -1|
| Severe                           | 2                                                                           |   |
| Mild                             | 1 Rhodanine positive granules                                              |   |
| Absent                           | 0                                                                           |   |
| Serum ceruloplasmin             | Urinary copper (in the absence of hepatitis)                               |
| Normal (>0.2g/L)                | 0 Normal                                                                   | 0 |
| (0.1-0.2 g/L)                    | 1 1-2x ULN                                                                 | 1 |
| (<0.1 g/L)                      | 2 >2x ULN                                                                  | 2 |
| Coombs negative Hemolytic Anaemia| Mutation analysis                                                          |   |
| Present                          | 1 On both chromosomes detected                                              | 4 |
| Absent                           | 0 On 1 chromosomes detected                                                | 1 |
|                                 | No mutation detected                                                       | 0 |
| Total score                      | Evaluation                                                                 |
| 4 or more                        | Diagnosis established                                                      |
| 3                                | Diagnosis is possible, more test needed                                    |
| 2 or less                        | Diagnosis very unlikely                                                    |

**TABLE 1: Leipzig score: adapted from scoring system developed at the 8th international meeting on Wilson’s disease [5].**

It comprises many key investigations for making the diagnosis of Wilson’s disease and applies to the adult population [5]. The Leipzig score was calculated for our patient and it was more than 4 confirming our diagnosis. The mainstay therapy for Wilson’s disease is copper chelation therapy with D-penicillamine and trientine. Trientine is preferred because of fewer side effects. Oral zinc may also be administered as it competes with copper for absorption at metallic ion transporter sites [6,7].

Tetrathiomolybdate (TM) is preferred over zinc in case of neurological involvement but availability and high cost are a challenge in resource-poor settings. It is vital to educate the patient on the adverse effects of chronic chelation therapy, which can make symptoms worse.

For muscle rigidity, spasticity, and parkinsonian features, muscle relaxants, including baclofen,
anticholinergic (trihexyphenidyl), gamma-aminobutyric acid antagonists, and levodopa, may be used.

Patient education regarding dietary modifications, such as avoidance of hepatotoxic medications, alcohol, and diet rich in copper including mushrooms, chocolate, nuts, dried fruits, liver, and shellfish, should be emphasized. As copper-chelating treatments take up to six months to start working, physiotherapy and occupational therapy are beneficial in the neurological form of the disease.

Long-term monitoring is essential with measurements of urinary copper, complete blood counts, free copper, and renal and liver function at 4- to 8-week intervals. Most patients need lifelong chelation therapy with follow-up. If untreated, the disease will eventually lead to chronic liver disease and may even progress to hepatocellular carcinoma in some cases. Genetic counseling is necessary to prevent the transmission of the defective gene.

Conclusions

Wilson’s disease is a genetic disorder that can have a variety of presentations and can be controlled if detected early. The treatment modality is lifestyle modification, proper follow-up, and physiotherapy. If disease control is not achieved after initial treatment, titrating the dose of chelating agent is indicated to prevent the damage of the internal organs.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institute Ethical Committee–AIIMS, Raipur issued approval not applicable. Te informed consent has been taken from the patient prior to the writing of the manuscript and the identity of the patient won’t be disclosed at any cost. Since this is a case report IEC approval is not mandatory; the patient has already consented for his case to be published in any journal. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW: The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993, 5:327-37. 10.1038/ng1295-327
2. Tanzi RE, Petrukhin K, Chernov I, et al.: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1995, 5:544-50. 10.1038/ng1295-544
3. Roberts EA: Update on the diagnosis and management of Wilson disease. Curr Gastroenterol Rep. 2018, 20:56. 10.1007/s11894-018-0660-7
4. Ferenci P, Steindl-Munda P, Vogel W, et al.: Diagnostic value of quantitative hepatic copper determination in patients with Wilson’s disease. Clin Gastroenterol Hepatol. 2005, 5:811-8. 10.1016/s1542-3565(05)00181-3
5. Ferenci P, Caca K, Loudianos G, et al.: Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003, 23:139-42. 10.1046/j.1477-2574.2003.00824.x
6. Gupta P, Choksi M, Goel A, et al.: Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson’s disease in resource constrained setting. Indian J Gastroenterol. 2018, 37:31-8. 10.1007/s12664-018-0829-x
7. Brewer GJ, Askari FK: Wilson’s disease: clinical management and therapy. J Hepatol. 2005, 42:513-21. 10.1016/j.jhep.2004.11.013